Bellevue Group Ag Moon Lake Immunotherapeutics Transaction History
Bellevue Group Ag
- $6.38 Billion
- Q1 2024
A detailed history of Bellevue Group Ag transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Bellevue Group Ag holds 4,400 shares of MLTX stock, worth $185,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,400Holding current value
$185,680% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$918 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$358 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$109 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$97.5 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$96.4 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.56B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...